RE: Licensing v's M&A outright sale for SNG8 May 2021 09:46
Licensing would normally indicate the best, long term, value for shareholders and would be my preference. But.....
If a take over does pop up, I would need to see the deal. A straight cash offer would likely be a no from me. Basically is another company can put a cash value on us, then they see a ROI large enough to gain acceptance from their own shareholders. Therefore, in my mind, an all cash offer will, by definition, be an undervaluation.
A paper or paper/cash offer, now that could be interesting. If from the right buyer (big pharma with other promising drugs in the pipeline along with the expertise and reach to make best use of SNG001) then I would be very interested and would take a careful look. Even if it is at a lower than a cash only equivalent, the opportunity to segue into their dividend stream, growth and dividend stream may well be too compelling.
It would depend on the who, what and why. A properly structured paper/cash offer may well be the best long term result for my pension fund!